Biohaven Net Profit Margin 2016-2023 | BHVN

Biohaven net profit margin from 2016 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
Biohaven Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-06-30 $0.16B $-0.24B -155.48%
2021-03-31 $0.07B $-0.21B -293.06%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.414B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $135.883B 8.30
GSK (GSK) United Kingdom $69.205B 9.66
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.425B 22.01
Ginkgo Bioworks Holdings (DNA) United States $3.504B 0.00
Arcus Biosciences (RCUS) United States $1.484B 0.00
Emergent Biosolutions (EBS) United States $0.414B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.183B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00